Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritis

Arthritis and Rheumatism

Volumn 52, Issue 10, 2005, Pages 3239-3247

  Koenders, Marije I ^a   Kolls, Jay K ^b,c   Oppers Walgreen, Birgitte ^a   Van Den Bersselaar, Liduine ^a   Joosten, Leo A B ^a   Schurr, Jill R ^c   Schwarzenberger, Paul ^c   Van Den Berg, Wim B ^a   Lubberts, Erik ^a,c,d  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^c LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3; CYCLOOXYGENASE 2; GELATINASE B; INTERLEUKIN 1; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 6; STROMELYSIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; BACTERIAL ARTHRITIS; BACTERIAL CELL WALL; CARTILAGE CELL; CARTILAGE DEGENERATION; CELL INFILTRATION; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DEFICIENCY; QUANTITATIVE DIAGNOSIS; STREPTOCOCCUS; STREPTOCOCCUS INFECTION; SURFACE TENSION; SYNOVIUM; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; ARTHRITIS, EXPERIMENTAL; CARTILAGE; CELL DEATH; CHONDROCYTES; CHRONIC DISEASE; COLLAGENASES; DISEASE MODELS, ANIMAL; FEMALE; INTERLEUKIN-1; INTERLEUKIN-17; MALE; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; RNA, MESSENGER; SIGNAL TRANSDUCTION; SPECIFIC PATHOGEN-FREE ORGANISMS; STREPTOCOCCUS; SYNOVIAL MEMBRANE;

EID: 26844554064     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21342     Document Type: Article

References (36)

1. Firestein GS, Zvaifler NJ. How important are T cells in chronic rheumatoid synovitis? [editorial]. Arthritis Rheum 1990;33:768-73.
2. Taylor PC. Anti-TNFα therapy for rheumatoid arthritis: an update. Intern Med 2003;42:15-20.
3. Bresnihan B. Anakinra as a new therapeutic option in rheumatoid arthritis: clinical results and perspectives. Clin Exp Rheumatol 2002;20 Suppl 27:S32-4.
4. Van den Berg WB, Joosten LA, Kollias G, van de Loo FA. Role of tumour necrosis factor α in experimental arthritis: separate activity of interleukin 1β in chronicity and cartilage destruction. Ann Rheum Dis 1999;58 Suppl I:I40-8.
5. Nakae S, Saijo S, Horai R, Sudo K, Mori S, Iwakura Y. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci U S A 2003;100:5986-90.
6. Lubberts E. The role of IL-17 and family members in the pathogenesis of arthritis. Curr Opin Investig Drugs 2003;4:572-7.
7. Miossec P. Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy [review]. Arthritis Rheum 2003;48:594-601.
8. Lubberts E, Joosten LA, Oppers-Walgreen B, van den Bersselaar L, Coenen-de Roo CJ, Kolls JK, et al. IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol 2001;167:1004-13.
9. Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de Roo CJ, Joosten LA, et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004;50:650-9.
10. Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003;171:6173-7.
11. Ye P, Rodriguez FH, Kanaly S, Stocking KL, Schurr J, Schwarzenberger P, et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defence. J Exp Med 2001;194:519-27.
12. Van den Broek MF, Hogervorst EJ, van Bruggen MC, van Eden W, van der Zee R, van den Berg WB. Protection against streptococcal cell wall-induced arthritis by pretreatment with the 65-kD mycobacterial heat shock protein. J Exp Med 1989;170:449-66.
13. Lubberts E, van den Bersselaar L, Oppers-Walgreen B, Schwarzenberger P, Coenen-de Roo CJ, Kolls JK, et al. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the RANKL/OPG balance. J Immunol 2003;170:2655-62.
14. Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS, et al. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 1996;14:1675-80.
15. Van den Berg WB, Joosten LA, van de Putte LB. Electrical charge of the antigen determines intraarticular handling and chronicity of arthritis in mice. J Clin Invest 1984;74:1850-9.
16. Lubberts E, Joosten LA, Chabaud M, van den Bersselaar L, Oppers-Walgreen B, Coenen-de Roo CI, et al. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest 2000;105:1697-10.
17. Joosten LA, Koenders MI, Smeets RL, Heuvelmans-Jacobs M, Helsen MM, Takeda K, et al. Toll-like receptor 2 pathway drives streptococcal cell wall-induced joint inflammation: critical role of myeloid differentiation factor 88. J Immunol 2003;171:6145-53.
18. Chabaud M, Durand JM, Buchs N, Fossiez F, Page G, Frappart L, et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999;42:963-70.
19. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999;103:1345-52.
20. Ziolkowska M, Koc A, Luszczykiewics G, Ksiezopolska-Pietrzak K, Klimczak E, Chwalinska-Sadowska H, et al. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 2000;164:2832-8.
21. Yao Z, Fanslow WC, Seldin MF, Rousseau AM, Painter SL, Comeau MR, et al. Herpes saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 1995;3:811-21.
22. Jovanovic DV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y, Zhang M, et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-1β and TNFα, by human macrophages. J Immunol 1998;160:3513-21.
23. Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1995;183:2593-603.
24. Chabaud M, Fossiez F, Taupin JL, Miossec P. Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol 1998;161:409-14.
25. Nakae S, Komiyama Y, Nambu A, Sudo K, Iwase M, Homma I, et al. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 2002;17:375-87.
26. Chabaud M, Garnero P, Dayer JM, Guerne PA, Fossiez F, Miossec P. Contribution of interleukin-17 to synovium matrix destruction in rheumatoid arthritis. Cytokine 2000;12:1092-9.
27. Jovanovic DV, Martel-Pelletier J, Di Battista JA, Mineau F, Jolicoeur FC, Benderdour M, et al. Stimulation of 92-kd gelatinase (matrix metalloproteinase 9) production by interleukin-17 in human monocyte/macrophages: a possible role in rheumatoid arthritis. Arthritis Rheum 2000;43:1134-44.
28. Lubberts E, Joosten LA, van de Loo FA, van den Bersselaar L, van den Berg WB. Reduction of interleukin-17-induced inhibition of chondrocyte proteoglycan synthesis in intact murine articular cartilage by interleukin-4. Arthritis Rheum 2000;43:1300-6.
29. Chabaud M, Lubberts E, Joosten LA, van den Berg WB, Miossec P. IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res 2001;3:168-77.
30. Dudler J, Renggli-Zulliger N, Busso N, Lotz M, So A. Effect of interleukin-17 on proteoglycan degradation in murine knee joints. Ann Rheum Dis 2000;59:529-32.
31. Koshy PJ, Henderson N, Logan C, Life PF, Cawston TE, Rowan AD. Interleukin-17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines. Ann Rheum Dis 2002;61:704-13.
32. Van Bezooijen RL, van der Wee-Pals L, Papapoulos SE, Lowik CW. Interleukin-17 synergises with tumour necrosis factor α to induce cartilage destruction in vitro. Ann Rheum Dis 2002;61:870-6.
33. Cai L, Yin JP, Starovasnik MA, Hogue DA, Hillan KJ, Mort JS, et al. Pathways by which interleukin-17 induces articular cartilage breakdown in vitro and in vivo. Cytokine 2001;16:10-21.
34. Benderdour M, Tardif G, Pelletier JP, Di Battista JA, Reboul P, Ranger P, et al. Interleukin-17 (IL-17) induces collagenase-3 production in human osteoarthritic chondrocytes via AP-1 dependent activation: differential activation of AP-1 members by IL-17 and IL-1β. J Rheumatol 2002;29:1262-72.
35. Sylvester J, Liacini A, Li WQ, Zafarullah M. Interleukin-17 signal transduction pathways implicated in inducing matrix metalloproteinase-3, -13, and aggrecanase-1 genes in articular chondrocytes. Cell Signal 2004;16:469-76.
36. Koenders MI, Lubberts E, Oppers-Walgreen B, van de Bersselaar L, Helsen MM, Kolls JK, et al. Induction of cartilage damage by overexpression of T cell interleukin-17A in experimental arthritis in mice deficient in interleukin-1. Arthritis Rheum 20005;52:975-83.